Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet MEMPOGLYN 5mg / 850mg film-coated tablets
- Product code:
- W72081001
- Quantity:
- 10
- Indicated for:
- type 2 diabetes mellitus
- Route of administration:
- oral
- Substance:
- empagliflozin + metformin (SGLT2 inhibitor+biguanide antidiabetic)
- ATC
- A10BD20 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs
Empagliflozin and metformin are medications used in combination to treat type 2 diabetes. This combination helps control blood sugar levels through complementary mechanisms and is particularly indicated for patients who cannot maintain adequate blood sugar control with metformin or other treatments alone.
Empagliflozin is an SGLT2 inhibitor (sodium-glucose co-transporter 2) that lowers blood sugar by eliminating excess glucose through the urine. Additionally, it provides cardiovascular and renal benefits, reducing the risk of heart failure and cardiovascular death in patients with type 2 diabetes.
Metformin, on the other hand, is a biguanide that decreases glucose production in the liver and improves insulin sensitivity in cells. It is considered the first-line treatment for type 2 diabetes due to its effectiveness and safety profile.
This combination is taken as oral tablets, usually twice daily with meals, to reduce the risk of gastrointestinal side effects. It is important for patients to follow their doctor’s instructions and regularly monitor blood sugar levels to assess the treatment’s effectiveness.
Side effects may include nausea, diarrhea, urinary or genital infections, and, in rare cases, lactic acidosis (associated with metformin) or diabetic ketoacidosis (associated with empagliflozin). Patients with severe renal impairment or other serious conditions should avoid this combination, and regular monitoring of kidney function is essential.
Empagliflozin is an SGLT2 inhibitor (sodium-glucose co-transporter 2) that lowers blood sugar by eliminating excess glucose through the urine. Additionally, it provides cardiovascular and renal benefits, reducing the risk of heart failure and cardiovascular death in patients with type 2 diabetes.
Metformin, on the other hand, is a biguanide that decreases glucose production in the liver and improves insulin sensitivity in cells. It is considered the first-line treatment for type 2 diabetes due to its effectiveness and safety profile.
This combination is taken as oral tablets, usually twice daily with meals, to reduce the risk of gastrointestinal side effects. It is important for patients to follow their doctor’s instructions and regularly monitor blood sugar levels to assess the treatment’s effectiveness.
Side effects may include nausea, diarrhea, urinary or genital infections, and, in rare cases, lactic acidosis (associated with metformin) or diabetic ketoacidosis (associated with empagliflozin). Patients with severe renal impairment or other serious conditions should avoid this combination, and regular monitoring of kidney function is essential.
General data about MEMPOGLYN 5mg / 850mg
- Substance:
- empagliflozin + metformin
- Date of latest medicines list:
- 01-08-2026
- Product code:
- W72081001
- Concentration:
- 5mg / 850mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 10
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for empagliflozin + metformin
- 12.5mg/1000mg
- 12.5mg/850mg
- 5mg/1000mg
- 5mg/850mg
Precautions:
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.